THE 2-MINUTE RULE FOR LINSITINIB FDA

The LIDS trial fulfilled its primary endpoint with statistical importance for the 150mg BID dose. Linsitinib In this particular demo validated the security profile observed from the prior oncology research and importantly demonstrated a good protection profile on critical adverse events (AEs) of interest for your IGF-1R goal for instance hearing im